Примери за използване на Randomised to receive either на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
double-blind, placebo-controlled study, 539 obese adolescent patients were randomised to receive either 120 mg orlistat(n=357)
279 patients were randomised to receive either placebo(Group 1,
279 patients were randomised to receive either placebo(Group 1,
include data from 742 women who were diagnosed with pre-term labour at 23-33 weeks of gestation and were randomised to receive either atosiban(according to this labelling) or-agonist(dose-titrated).
include data from 742 women who were diagnosed with pre-term labour at 23-33 weeks of gestation and were randomised to receive either atosiban(according to this labelling) or β-agonist(dose-titrated).
were randomised to receive either cinacalcet in addition to standard of care(SOC,
1491 patients were randomised to receive either docetaxel 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m
1491 patients were randomised to receive either docetaxel 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2
552 patients with relapsed/refractory CLL were randomised to receive either FC chemotherapy(fludarabine 25 mg/m2,
were randomised to receive either placebo(n=172) or lacosamide(n=171).
were randomised to receive either dolutegravir 50 mg twice daily
antiretroviral-naïve patients received a lead-in dose of Viramune 200 mg immediate-release once daily for 14 days(n=1068) and then were randomised to receive either Viramune 200 mg immediate-release twice daily
treatment-naïve patients received a lead-in dose of Viramune 200 mg immediate-release once daily for 14 days and then were randomised to receive either Viramune 200 mg immediate-release twice daily
Patients were randomised to receive either 200 mg(N=631)
12 years of age with organic and/or idiopathic GHD were randomised to receive either weekly administered Somatropin Biopartners(0.5 mg/kg/week)
552 patients with relapsed/refractory CLL were randomised to receive either FC chemotherapy(fludarabine 25 mg/m2,
A total of 906 patients were randomised to receive either nivolumab 3 mg/kg(n= 453)
radiographic disease progression despite primary androgen deprivation therapy who were randomised to receive either enzalutamide at a dose of 160 mg once daily(N= 198)
A total of 405 patients were randomised to receive either nivolumab(n= 272) administered intravenously over 60 minutes
a total of 322 previously untreated patients with follicular lymphoma were randomised to receive either CVP chemotherapy(cyclophosphamide 750 mg/m2,